These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Consensus statement to Schering-Plough Pharmaceuticals from the health care community regarding Rebetron development and marketing.
    Journal: Notes Undergr; 1999; (No 39):9-13. PubMed ID: 11366786.
    Abstract:
    A consensus statement regarding Schering-Plough's unethical dispensing practices for Rebetol (Ribavirin) has been issued by a coalition of organizations and individuals affected by hepatitis C (HCV). The statement demands that Ribavirin be unbundled from Intron-A; that the price of Ribavirin be immediately lowered to more closely match the cost of other drugs in the same nucleoside analogue class; and that HCV viral load results be unblinded for participants in Schering-Plough clinical trials. Endorsers of the statement also demand that Schering-Plough create access to Rebetol for those who cannot afford it and, until it is unbundled, create access to Ribavirin for those who wish to use it in combination with another Interferon. Each of these demands is described in detail. The organizations and individuals endorsing the consensus statement are listed.
    [Abstract] [Full Text] [Related] [New Search]